President and Managing Partner
Peter Latham has twenty years in general management and thirteen years in financial, strategic and business development consulting to the biotech industry. As founder and president of New Venture Advisors, Inc., then BioPharm Services, Inc. (which became Latham BioPharm Group), Mr. Latham has worked with a variety of companies ranging from large pharmaceutical companies to biotechs, venture capitalists and start-up entities. He has served as Acting President and on a variety of boards for clients ranging from start-ups to publically traded companies. Prior to this, Mr. Latham was V.P. Engineering and Licensing for Drug Delivery Development, Inc. (DDD) where he managed the US operations and negotiated several large licenses for a drug delivery firm based in France. Prior to DDD, Mr. Latham was Subsystem Manager at McDonnell Douglas responsible for all of the cargo handling systems and interiors on the USAF C-17 program.
Mr. Latham holds a B.S. in Mechanical Engineering from Rensselaer Polytechnic Institute, an M.S. in Management from Massachusetts Institute of Technology’s Sloan School, and is a certified Program Manager (PgMP) with the PMI.
Susan Dexter has over twenty-five years of experience in biotechnology science and business development. Ms. Dexter worked as a scientist doing cell culture and small scale manufacturing, before moving into the business of science and selling biotechnology contract manufacturing services ranging from process development through commercial manufacturing, and strategic consulting related services. Ms. Dexter has supported multiple start-up companies as well as established biotech, pharmaceutical and technology companies, performing strategic business development, M&A , and technology in- and out-licensing. Prior to joining Latham Biopharm Group, Ms. Dexter was Chief Business Officer at Xcellerex, Inc. responsible for all aspects of business development for contract manufacturing services (CMO), and the sale of disposable technologies and integrated modular manufacturing facilities (FlexFactory®). Prior to Xcellerex, Ms. Dexter was the VP of Business Development at The Dow Chemical Company after developing a $7.0M CMO business at the Collaborative BioAlliance, and then selling it to Dow. She was also the Assoc. Director of Business Development (and was the first US employee) of Celltech, then Lonza, where she identified and closed commercial supply agreements in excess of $650M and negotiated over twenty gene expression technology licenses worth over $250M.
Ms. Dexter holds a double major with Honors in Immunology and Marketing from American University, Washington, D.C., a graduate of the ‘Negotiation for Lawyers” course, Harvard University; she also lectures annually at University College London (credit course) and presents regularly at a variety of industry conferences.
Managing Director, Government Practice Lead
Michael McGinnis has almost twenty years of international business development, strategic planning, marketing, program management and general management experience in the Pharmaceutical and Biotechnology industries. He has senior level experience in both the commercial and government sectors, and a strong track record of achieving organizational growth targets. Most recently, as Director of New Business for DynPort Vaccine Company (DVC – a reputable biodefense product development organization within the Fortune 200 company CSC), Mr. McGinnis was responsible for leading the company’s new business activities and functions in the US Government sector. He was actively engaged with client organizations including CBMS, DTRA, BARDA and NIAID and teaming partners, i.e. CROs, Pharma/Biotech, and CMOs. As part of this role, Mr. McGinnis was responsible for all aspects of new business, including providing strategic oversight of both technical and budgetary aspects of proposals in response to US Government medical countermeasure advanced development program solicitations. Prior to joining DVC, he worked at ICON Clinical Research, as Executive Director of Sales, and at MedTrials, Inc. as the Associate Director of Business Development & Marketing, and held various leadership roles with global business development and marketing responsibilities for the CROs in the Biopharmaceutical, Pharma and Medical Device industries.
Mr. McGinnis earned a B.S. in Business Administration from Towson University, an M.B.A. from Loyola University Maryland, and an M.S. in Biotechnology from Johns Hopkins University.
Mr. Newton has over thirty years of experience in the design and management of technical development programs often working directly with government agencies. He has managed the design, build and validation of specialized pharmaceutical automation systems and instruments and the development of advanced concepts for manufacturing of pharmaceuticals. In his last position, Mr. Newton was Division Manager at Foster Miller, now QinetiQ North America, where in addition to building the business segment, he managed the early stage development of a technology for manufacturing drug products in a miniaturized system for battlefield applications. Prior to Foster Miller, Mr. Newton was Director of Thermal Technologies for OHM Remediation Services where he was responsible for the design, installation and validation of chemical process systems under the EPA Superfund program . In these capacities and at Latham BioPharm Group, Mr. Newton has won and managed projects working with the U.S. Navy, Army Corps of Engineers and DARPA.
Mr. Newton holds both a B.S. and an M.S. in Mechanical Engineering from Tufts University and is an active member of ISPE, PMI, and ALA.
Joshua Speidel, Ph.D.
Managing Director, Commercial Practice Lead
Dr. Joshua Speidel has eight years of experience managing pre-discovery programs to the lifecycle management of mature products post-licensure. With Latham BioPharm Group (LBG), Dr. Speidel has led teams in the submission of proposals resulting in >$89M of awards. Dr. Speidel provides federal contract compliance services and technical expertise to clients and contributes to the operational management of LBG. As a Health Scientist for the U.S. Department of Health and Human Services (HHS), Biomedical Research and Development Authority (BARDA), he assisted and led teams responsible for the established core capabilities to support the licensure of medical countermeasures in the areas of manufacturing capacity, product development, clinical studies, and long-term stockpiling. While consulting to the U.S. Defense Advanced Research Projects Agency (DARPA), Dr. Speidel created programmatic concepts that were pitched to DARPA’s director and resulted in excess of $250M in contract awards, was the technical point of contact for two teams in the “Accelerated Manufacturing of Pharmaceuticals” program which pioneered efforts in recombinant vaccine production, and was the project manager for their $100M response to the H1N1 pandemic, advancing a pre-discovery stage vaccine candidate through a Phase 1 Clinical Trial, on time and on budget.
Dr. Speidel received a Ph.D. in Physiology and Biophysics from Cornell University, a M.Sc. in Biochemistry and Biophysics from the University of Houston and a B.S. in Biochemistry and Molecular Biology from Pennsylvania State University.
Robert Huebner, Ph.D.
Dr. Robert Huebner is an experienced biotechnology program manager with over twenty-five years of research experience with viral and microbiological pathogens and expertise in the vaccine industry, group management, and program management. Throughout his career, he has worked for a variety of organizations, large pharma companies, government agencies, and a contract research organization, holding positions of increasing responsibility at each. Most recently, while working at the Biomedical Research and Development Authority (BARDA) of the Department of Health and Human Services, Dr. Huebner held several positions including Acting Director of the Influenza Division, Deputy Director and Chief of Universal Influenza Vaccine Development. While serving as Acting Director, he was responsible for over 50 programs valued in excess of $5 billion, highlighted by the licensure of three new types of influenza vaccines, and approval of a new near patient diagnostic platform for influenza and RSV. Prior to BARDA, at the Midwest Research Institute, now MRIGlobal, Dr. Huebner grew the client base for the biotechnology section he managed, bringing in awards from: the Department of Homeland Security for pathogen sensor development; the FDA’s Center for Food Safety and Applied Nutrition for pathogen detection in food; DynPort Vaccine Corporation (DVC) for assessment of vaccines in animal models; and other industrial clients for aerosol sciences studies. Dr. Huebner started his career as a bench scientist and group leader at Connaught Laboratories, now Sanofi Pasteur, working on applied research to develop new and improved vaccines against Lyme disease, influenza, Dengue, Japanese Encephalitis, malaria and pneumococcal disease.
Dr. Huebner received a Ph.D. in Molecular Biology and Microbiology from Tufts University in Boston, MA and a B.S. in Biology from Carnegie Mellon University, Pittsburgh, PA.
Joseph Rininger, Ph.D.
Dr. Rininger possesses over eighteen years of experience in basic biomedical research and biopharmaceutical product development program management with an emphasis on vaccines, adjuvants and gene therapy. As the Senior Director, Influenza at Protein Sciences Corporation (PSC), Dr. Rininger was the program manager of a BARDA contract for the advanced development and commercialization of Flublok®, the first approved recombinant hemagglutinin-based subunit vaccine for influenza. This encompassed planning and leading a cross-functional team in the execution of tasks involving all areas of recombinant vaccine development (process development, formulation development and stability, pre-clinical efficacy and toxicology, quality control/quality systems, process and facility validation, manufacturing process transfer, regulatory affairs and clinical development).
Prior to that role, he served as Director of Business Development and worked to secure new CMO programs, grew an established research product business unit evaluated in- and out-licensing of technology and performed writing and submission of NIH grant funding opportunities. He has solid skills in international business development, strategy and alliance management; working with CMOs, CROs, medical device company sterile filling technology, For the CMO projects PSC, he successfully oversaw project teams for the development of upstream and downstream processes for transfer to cGMP manufacturing of four vaccine candidates and two biologics. He also has experience in product development and program management of rAAV-based gene therapies and had a supportive regulatory role in the approval of Glybera, the first gene therapy to attain marketing approval. He has also supported three rAAV development programs for orphan diseases and authored the CMC section for a program that has entered human clinical trials.
Dr. Rininger earned a Ph.D. from Cornell University in Toxicology and a B.S. in Marine Biology with a Concentration in Biotechnology from Fairleigh Dickinson University. He has several awarded and pending patents and is well published in industry magazines and peer-reviewed journals.
Ms. Sarno holds twenty years of industry experience, including roles in business development, strategic alliance, project management, and research. She has experience negotiating, closing, and maintaining research agreements and technology licenses with multiple biologics technology platforms. At Latham BioPharm Group (LBG), Ms. Sarno is a Senior Consultant and provides business development consulting and program management services to clients. Before coming to LBG, she served as Director of Business Development for Pfenex, Inc., a biosimilar company that launched its product portfolio from its proprietary protein production platform. At Pfenex, Ms. Sarno was responsible for business development, market analysis, and strategic recommendations for both individual programs and the pipeline portfolio.
Prior to Pfenex, Ms. Sarno held roles at Laureate Biopharmaceuticals (now part of Patheon), where she was responsible for bringing in new Phase I biologics manufacturing clients, and Crucell, where she supported the Per.C6 human cell line protein production technology platform. Her early career was spent in research positions with venerable institutions such as Boston Children’s Hospital, Beth Israel Deaconess, and the American Red Cross.
Ms. Sarno earned her ALM (Master of Liberal Arts) in Biology at Harvard University, and her BS in Biology at Syracuse University, and is the National President Emeritus of Women in Bio (WIB), an organization of professionals committed to promoting careers, leadership and entrepreneurship for women in the life sciences.
Gretchen Stup brings more than fifteen years of experience in the management of government contracts, and over seventeen total years of experience working in a scientific environment to Latham BioPharm Group. At LBG, she serves as a Senior Consultant where she provides program management and systems integration support to government and client related projects for companies of different sizes. She is a certified Project Management Professional (PMP) and much of her experience lies in total project lifecycle management. Ms. Stup has successfully managed multiple government contracts, including Plague, Tularemia, Ebola, and Anthrax vaccine development projects. She supported the development of Vaccinia Immune Globulin (VIGIV), which was one of the first FDA-licensed biodefense products. Besides her in-depth experience in the management of government (including Prime) contracts, she has been involved in the management and oversight of various subcontracting organizations, ranging from small R&D facilities to large, complex CMOs and CROs. Ms. Stup has experience with the Animal Rule and has supported FDA filings and negotiations through product licensure. Prior to working in Program Management at LBG and previously at DynPort Vaccine Company (DVC), she co-developed and implemented DVC’s comprehensive Risk Management program, and worked as a Quality Assurance specialist at Boston Biomedica, Inc. (now Pressure BioSciences, Inc.).
Ms. Stup earned a Bachelor of Science degree from Shepherd University and is a Project Management Professional (PMP) as certified by the Project Management Institute.
Cassidy Cantin has worked within the Life Sciences industry for the better half of a decade providing Program Management and Product Leadership with specific experience on vaccine and biosimilar development, as well as Business Development and Marketing expertise. As a Consultant for Latham BioPharm Group (LBG), Ms. Cantin will continue to use her knowledge of program management to help clients manage the successful planning and delivery of their government and commercial programs. Her extensive skills in primary and secondary market research and competitive intelligence analysis will assist clients in making strategic decisions and developing their corporate strategy. Prior to LBG, Ms. Cantin was the Senior Manager of Business Development and Marketing at Pfenex Inc., a biologics company focused on biosimilar development. In addition to her business development and marketing responsibilities there, she managed government sponsored programs totaling over $30M and supported a number of successful government proposal efforts.
Ms. Cantin holds an MBA from San Diego State University with an emphasis in entrepreneurship and market research. She did her undergraduate work at University of California, San Diego where she earned a B.A. double major in Economics and Public Health. Ms. Cantin is currently serving as the President-Elect for Women In Bio (WIB), an organization of professionals committed to promoting careers, leadership and entrepreneurship for women in the life sciences.
Ms. Farley has over twenty years’ experience supporting small businesses and in the hospitality industry. At Latham BioPharm Group, she is active in the provision of Marketing Services both internally and to our clients including the generation of marketing materials, advertising and trade show booths. Additionally, Ms. Farley actively supports market research projects in the recruiting of respondents and generation of reports. On the government funding front, Ms. Farley has extensive experience in and supports the drafting of proposals and prepares the monthly Government Funding Opportunities Report for our clients. Finally, Ms. Farley handles all of the traditional administrative roles including the office management at Latham BioPharm Group.
Ms. Farley holds a BA in Political Science from the University of Maine.